Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 1 AUD -1.48% Market Closed
Market Cap: 271.1m AUD
Section:
 

Relative Value

The Relative Value of one OCC stock under the Base Case scenario is hidden AUD. Compared to the current market price of 1 AUD, Orthocell Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OCC Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

29.4
P/S
P/S
Price to Sales
29.4
vs History
71
vs Industry
21
Median 3Y
31.9
Median 5Y
42.2
Industry
8.1
Forward
9.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-15.4
Industry
23.7
Forward
-495
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
13
Median 3Y
-16.9
Median 5Y
-20.3
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
10
Median 3Y
-14.7
Median 5Y
-18.9
Industry
25.7
More Details
18.6
P/B
P/B
Price to Book Value
18.6
vs History
36
vs Industry
4
Median 3Y
20.8
Median 5Y
16.8
Industry
3.3
More Details
26.3
EV/S
EV/S
Enterprise Value to Sales
26.3
vs History
68
vs Industry
18
Median 3Y
26.3
Median 5Y
39
Industry
8.4
Forward
8.5
More Details
37.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
37.5
vs History
63
vs Industry
14
Median 3Y
34.7
Median 5Y
53.1
Industry
10.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-10.5
Industry
5.9
Forward
-7 072.9
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-8.8
Median 5Y
-10.5
Industry
6.4
Forward
-709.4
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
14
Median 3Y
-13.9
Median 5Y
-18.1
Industry
8.2
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
10
Median 3Y
-12.4
Median 5Y
-17.1
Industry
6.4
More Details
54.9
EV/IC
EV/IC
Enterprise Value to IC
54.9
vs History
22
vs Industry
6
Median 3Y
28.3
Median 5Y
33.8
Industry
5.8
More Details

Multiples Across Competitors

OCC Competitors Multiples
Orthocell Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Orthocell Ltd
ASX:OCC
271.1m AUD 29.4 -31.6 -20.7 -20.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 178 916.3 -162 447.3 -197 262.9 -195 011.9
US
Abbvie Inc
NYSE:ABBV
378.8B USD 6.4 161.3 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.8B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.9 12.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 061.2 -526 -572.7 -557.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85B AUD 3.7 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
42.4B EUR 13.7 32.1 55.1 56.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.8 1 086.8 146.4 177.6
P/S Multiple
Revenue Growth P/S to Growth
AU
Orthocell Ltd
ASX:OCC
Average P/S: 3 107 370.1
29.4
73%
0.4
FR
Pharnext SCA
OTC:PNEXF
34 178 916.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.3
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 061.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.4
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
NL
argenx SE
XBRU:ARGX
13.7
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.8
46%
0.3
P/E Multiple
Earnings Growth PEG
AU
Orthocell Ltd
ASX:OCC
Average P/E: 173.9
Negative Multiple: -31.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 447.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.3
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
32.1
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Orthocell Ltd
ASX:OCC
Average EV/EBITDA: 37.4
Negative Multiple: -20.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 262.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -572.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
55.1
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.4
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Orthocell Ltd
ASX:OCC
Average EV/EBIT: 43.1
Negative Multiple: -20.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 011.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
56.7
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.6
N/A N/A

See Also

Summary
OCC intrinsic value, competitors valuation, and company profile.
DCF Valuation
OCC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
OCC stock valuation using valuation multiples.
Wall Street Estimates
OCC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
OCC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 310,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.